Park Place Capital’s AstraZeneca AZN Stock Holding History

Park Place Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.5K	Buy	+140	New	+$26.3K	﹤0.01%	575
2026 Q1	–	Sell	-176	Closed	-$32.4K	–	853
2025 Q4	$32.4K	Buy	176 +36	+26%	+$6.31K	0.01%	395
2025 Q3	$21.5K	Hold	140	–	–	﹤0.01%	448
2025 Q2	$20K	Sell	140 -1,150	-89%	-$161K	﹤0.01%	476
2025 Q1	$190K	Hold	1,290	–	–	0.05%	188
2024 Q4	$169K	Sell	1,290 -531	-29%	-$74.3K	0.05%	217
2024 Q3	$284K	Hold	1,821	–	–	0.08%	176
2024 Q2	$284K	Buy	1,821 +531	+41%	+$79.9K	0.09%	177
2024 Q1	$175K	Hold	1,290	–	–	0.06%	250
2023 Q4	$174K	Buy	1,290 +753	+140%	+$97.9K	0.07%	241
2023 Q3	$72.7K	Sell	537 -1,150	-68%	-$157K	0.02%	410
2023 Q2	$241K	Buy	1,687 +763	+83%	+$112K	0.07%	221
2023 Q1	$128K	Hold	924	–	–	0.04%	303
2022 Q4	$125K	Buy	+924	New	+$116K	0.04%	312

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Park Place Capital's AZN Position: Q2 2026 in Review

Park Place Capital opened a new position in AstraZeneca (AZN) in Q2 2026: 140 shares worth $26.5K. The stake represents ﹤0.01% of the portfolio and ranks #575 among its holdings. This is a return to the name: Park Place Capital previously reported a position in AZN as recently as Q4 2025.

Park Place Capital first reported a position in AZN in Q4 2022 and has held it in 14 quarters since. The position peaked at $284K in Q2 2024. 1,505 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Park Place Capital held 140 shares of AstraZeneca worth $26.5K as of Q2 2026.
AstraZeneca was a new Park Place Capital position in Q2 2026.
AstraZeneca made up ﹤0.01% of Park Place Capital's portfolio in Q2 2026, its #575 holding.
Park Place Capital first reported a position in AstraZeneca in Q4 2022 and has held it in 14 quarters since.
Park Place Capital's AstraZeneca position peaked at $284K in Q2 2024.
1,505 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.